ResMed Posts Strong Q2 Growth on New Product Momentum and GLP-1 Therapy Tailwinds
ResMed Inc. reports an 11% revenue surge for its second fiscal quarter, driven by robust mask sales and strategic acquisitions, while navigating competitive pressures and capitalizing on emerging healthcare trends.